AFIB (Acutus Medical) 3-Year Book Growth Rate: 0.00% (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Acutus Medical 3-Year Book Growth Rate?

Acutus Medical AFIB 3-Year Book Growth Rate is 0.00% as of Dec. 2024.

Acutus Medical's Book Value per Share for the quarter that ended in Dec. 2024 was $-0.39.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Acutus Medical  (OTCPK:AFIB) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Acutus Medical 3-Year Book Growth Rate Related Terms

AFIB vs DHAI, ABT, BSX: 3-Year Book Growth Rate Comparison

For the Medical Devices subindustry, Acutus Medical's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acutus Medical 3-Year Book Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Acutus Medical's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Acutus Medical's 3-Year Book Growth Rate falls into.


Acutus Medical 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

What does a 3-Year Book Growth Rate of 0.00% mean?
Acutus Medical (AFIB) has a 3-Year Book Growth Rate of 0.00% as of Dec. 2024. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Acutus Medical and its competitors.
Is Acutus Medical's 3-Year Book Growth Rate too high?
Acutus Medical's current 3-Year Book Growth Rate is 0.00%.
How does Acutus Medical's 3-Year Book Growth Rate compare to DHAI and ABT?
Acutus Medical's 3-Year Book Growth Rate of 0.00% can be compared against companies in the Medical Devices & Instruments industry. The industry median 3-Year Book Growth Rate is 2.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Medical Devices & Instruments company?
The median 3-Year Book Growth Rate among Medical Devices & Instruments companies is 2.30, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Acutus Medical and its competitors. For the Medical Devices & Instruments industry, the median 3-Year Book Growth Rate is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acutus Medical's current 3-Year Book Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acutus Medical stock overvalued right now?
Acutus Medical (AFIB) has a current 3-Year Book Growth Rate of 0.00%. The current 3-Year Book Growth Rate is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Acutus Medical (AFIB), the current 3-Year Book Growth Rate is 0.00% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acutus Medical Business Description

Address 2210 Faraday Avenue, Suite 100, Carlsbad, CA, USA, 92008
Acutus Medical Inc is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. The company designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias. Its product portfolio includes Novel access sheaths, Transseptal crossing tools, Diagnostic and mapping catheters, Ablation catheters, Mapping, and imaging consoles and accessories, as well as Supporting algorithms and Software programs. It markets and sells its electrophysiology products world-wide to hospitals and electrophysiologists that treat patients with arrhythmias. It has a business presence in the United States and Outside the United States.